T2 Condition 1282 1284 AR
T3 Protein 789 805 CYP17 inhibitors
T4 Condition 1145 1161 tumor xenografts
T5 Intervention 1029 1036 nuclear
T7 Protein 1009 1015 apo-AR
T8 Biomarker 129 138 androgens
T9 Condition 868 870 AR
T10 Condition 1395 1397 AR
T11 Protein 829 838 orteronel
T12 Condition 370 372 AR
T13 Protein 1054 1057 DNA
T14 Biomarker 641 652 seviteronel
T15 Protein 1351 1367 CYP17 inhibitors
T16 Gene 1350 1357  CYP17 
T17 Protein 429 460 CYP17 lyase–selective inhibitor
T18 Biomarker 736 744 androgen
T19 Gene 35 56 cytochrome P450 17A1 
T20 Protein 251 255 CRPC
T21 Gene 927 951 CYP17 inhibitor–bound AR
T22 Gene 501 526 prostate-specific antigen
T23 Gene 428 435  CYP17 
T24 Protein 1443 1447 CRPC
T25 Biomarker 351 359 androgen
T26 Condition 1197 1214 mutation AR-F876L
T27 Protein 545 549 CRPC
T28 Biomarker 576 587 seviteronel
T29 Gene 788 795  CYP17 
T30 Biomarker 414 425 seviteronel
T31 Biomarker 129 137 androgen
T32 Protein 868 882 AR antagonists
T33 Protein 303 319 CYP17 inhibitors
T34 Condition 1005 1007 AR
T35 Biomarker 180 191 abiraterone
T36 Organism 532 539 patient
T37 Gene 351 368 androgen receptor
T38 Gene 302 309  CYP17 
T39 Condition 608 610 AR
T40 Condition 1206 1208 AR
T41 Biomarker 1109 1120 abiraterone
T42 Gene 926 933  CYP17 
T43 Biomarker 1093 1104 seviteronel
T44 Condition 213 249 castration-resistant prostate cancer
R1 Relation Arg1:T25 Arg2:T12
